Table 1.
Summary of the actions of the mitogen-activated protein kinases inhibitors
Inhibitor | Mechanism of action | Effects |
SP600125 | Selective and reversible inhibitor of JNK | Dose dependent inhibition of JNK Inhibition of inflammatory genes (COX-2, IFN, IL-2, TNF-α) in vivoReduction of pancreatic inflammatory mediators (TNF-α, IL-1β) in vivo |
CEP1347 | Potent and selective inhibitor of JNK | Dose dependent inhibition of JNK both in vivo than in vitroReduction of inflammatory cytokines |
PD98059 | Inhibitor of ERK 1/2, prevents phosphorylation binding MEK | Protection against inflammatory process in the pancreas in vivo Protective effects probably related to the inhibition of COX-2 |
UO126 | Selective inhibitor of MEK1 and MEK2; it prevents the activation of ERK1/2 | Protection against inflammatory process in the pancreas in vivo |
SB203580 | Selective inhibitor of p38. Inhibition of p38 catalytic activity | Downregulation of the expression of proinflammatory mediators (TNF-α and IL-1β) in vivo |
JNK: c-jun N-terminal kinase; COX-2: Cyclooxygenase 2; IFN: Interferon; IL: Interleukin; TNF: Tumor necrosis factor; ERKs: Extracellular signal-regulated kinases.